<DOC>
	<DOCNO>NCT01753154</DOCNO>
	<brief_summary>To investigate biocompatibility peritoneal dialysis ( PD ) solution balance comparison conventional PD solution APD ( automate peritoneal dialysis ) patient use APD cycler sleep•safe .</brief_summary>
	<brief_title>The Effect Balance PD Solution Peritoneal Membrane Patients Automated Peritoneal Dialysis</brief_title>
	<detailed_description>Equivalence investigational PD solution balance regard fluid status compare conventional PD solution . Effects balance inflammation systemic advance glycation end product formation . Effects balance peritoneal total urea clearance , peritoneal total creatinine clearance ultrafiltration , residual diuresis cholesterol level . Safety investigational PD solution balance conventional PD solution control drug . The mesothelial cell mass assess Cancer Antigen 125 affect use type PD solution APD patient use sleep•safe . Treating patient PD solution balance lead 1 litre difference hydration comparison conventional PD solution consider clinically relevant regard blood pressure .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>APD patient ≥ 18 year Prevalent patient least 3 month experience APD prior inclusion Patient train treat sleep•safe APD cycler Patient treat APD exclusively register conventional PD solution CAPD 2 , CAPD 3 , CAPD 4 , CAPD 17 , CAPD 18 CAPD 19 least 8 week prior inclusion Patient stable diuretic treatment e.g change diuretic treatment within last 30 day prior inclusion Informed consent sign date study patient investigator/authorised physician Ability understand nature requirement study Peritonitis treatment £ 4 week precede inclusion APD patient treat IPD modality ( intermittent peritoneal dialysis ) Malignant disease without remission Patients artificial joint , amputation , stent , pacemaker Patients congestive heart failure coronary artery disease NYHA ( New York Heart Association ) III higher Active HBV ( hepatitis B virus ) HCV ( hepatitis C virus ) infection HIV positive Participation interventional clinical study precede 30 day Any condition could interfere patient 's ability comply study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Peritoneal Dialysis</keyword>
	<keyword>Biocompatible dialysis solution</keyword>
	<keyword>Hydration status</keyword>
	<keyword>Residual renal function</keyword>
	<keyword>Body composition monitor</keyword>
	<keyword>Bioimpedance spectroscopy</keyword>
	<keyword>Cancer antigen 125</keyword>
</DOC>